Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first
Immune checkpoint inhibitors (ICIs) have expanded the arsenal of cancer therapeutics over the last decade but are associated with a spectrum of immune-related adverse events (irAEs), including inflammatory art...
Source: Pediatric Rheumatology - Category: Rheumatology Authors: John A. Storwick, Herman Tam, Daniel G. Rosenbaum and Kristin Houghton Tags: Case Report Source Type: research
More News: Arthritis | Cancer | Cancer & Oncology | Immunotherapy | Pediatrics | Rheumatology | Yervoy